Role of regulatory T cells and CD8+ T lymphocytes in the dissemination of circulating tumor cells in primary invasive breast cancer

Xue,Dandan; Xia,Tiansong; Wang,Jue; Chong,Meihong; Wang,Shui; Zhang,Chunhui

doi:10.3892/ol.2018.8993

Role of regulatory T cells and CD8+ T lymphocytes in the dissemination of circulating tumor cells in primary invasive breast cancer

Authors:
- Dandan Xue
- Tiansong Xia
- Jue Wang
- Meihong Chong
- Shui Wang
- Chunhui Zhang
View Affiliations

Affiliations: Department of Thyroid and Breast Surgery, The Affiliated Hospital of Nantong University, Nantong, Jiangsu, 226001, P.R. China, Breast Disease Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, 210029, P.R. China, Department of Thyroid and Breast Surgery, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, 225001, P.R. China
Published online on: June 19, 2018 https://doi.org/10.3892/ol.2018.8993
Pages: 3045-3053
Copyright: © Xue et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Circulating tumor cells (CTCs) dissemination is involved in tumor metastasis and is an independent prognostic factor in patients with primary and metastatic breast cancer. Regulatory T cells (Tregs) and cluster of differentiation (CD)8+ T lymphocytes are the main types of immune cells in the tumor microenvironment and exert opposite roles on the progression and outcome of breast cancer. The aim of the present study was to evaluate the associations between CTCs and intratumoral/peritumoral Tregs and CD8+ T lymphocytes in breast cancer. Peripheral CTCs were detected by a multi‑marker quantitative polymerase chain reaction platform in 167 patients with invasive breast cancer. Intratumoral/peritumoral Tregs and CD8+ T lymphocytes were assessed by immunohistochemistry in 167 patients with invasive breast cancer to establish an association between these cell types and detection of peripheral CTCs. CTCs were detected in 55% of the patients with breast cancer. The prevalence of CTCs was positively associated with the number of intratumoral (P=0.002) and peritumoral Tregs (P=0.045), and the primary tumor size (P=0.012). This result was verified by analyzing intratumoral Tregs (P=0.044) and primary tumor size (P=0.044) with multivariate analysis, which indicated that the CTC‑positive rate increased with an increasing number of intratumoral Tregs and a larger tumor size In the multivariate analysis, other variables including menopause, tumor‑node‑metastasis stage and peritumoral Tregs were not associated with the prevalence of CTCs. The prevalence of CTCs was inversely and weakly associated with the number of peritumoral CD8+ T lymphocytes using the univariate analysis, however this result was not statistically significant (P=0.470). In conclusion, regulatory T cells and CD8+ T lymphocytes may be involved, at least in part, in the CTCs dissemination of breast cancer, whereby Tregs appear to exert the dominant effect. Furthermore, the role of Tregs in the progression of breast cancer may be mediated by suppressing the dissemination of CTCs, which is primarily determined by intratumoral Tregs.

View Figures

View References

1	Hunter KW, Crawford NP and Alsarraj J: Mechanisms of metastasis. Breast Cancer Res. 10 Suppl 1:S22008. View Article : Google Scholar : PubMed/NCBI
2	Zhang L, Riethdorf S, Wu G, Wang T, Yang K, Peng G, Liu J and Pantel K: Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res. 18:5701–5710. 2012. View Article : Google Scholar : PubMed/NCBI
3	Smith HA and Kang Y: The metastasis-promoting roles of tumor-associated immune cells. J Mol Med. 91:411–429. 2013. View Article : Google Scholar : PubMed/NCBI
4	Wong CW, Lee A, Shientag L, Yu J, Dong Y, Kao G, Al-Mehdi AB, Bernhard EJ and Muschel RJ: Apoptosis: An early event in metastatic inefficiency. Cancer Res. 61:333–338. 2001.PubMed/NCBI
5	Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, Klein C, Saini M, Bäuerle T, Wallwiener M, et al: Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol. 31:539–544. 2013. View Article : Google Scholar : PubMed/NCBI
6	Santos MF, Mannam VK, Craft BS, Puneky LV, Sheehan NT, Lewis RE and Cruse JM: Comparative analysis of innate immune system function in metastatic breast, colorectal, and prostate cancer patients with circulating tumor cells. Exp Mol Pathol. 96:367–374. 2014. View Article : Google Scholar : PubMed/NCBI
7	Noman MZ, Messai Y, Muret J, Hasmim M and Chouaib S: Crosstalk between CTC, immune system and hypoxic tumor microenvironment. Cancer Microenviron. 7:153–160. 2014. View Article : Google Scholar : PubMed/NCBI
8	Kim ST, Jeong H, Woo OH, Seo JH, Kim A, Lee ES, Shin SW, Kim YH, Kim JS and Park KH: Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. Am J Clin Oncol. 36:224–231. 2013. View Article : Google Scholar : PubMed/NCBI
9	Al-Saleh K, Abd El-Aziz N, Ali A, Abozeed W, Abd El-Warith A, Ibraheem A, Ansari J, Al-Rikabi A, Husain S and Nabholtz JM: Predictive and prognostic significance of CD8⁺ tumor-infiltrating lymphocytes in patients with luminal B/HER 2 negative breast cancer treated with neoadjuvant chemotherapy. Oncol Lett. 14:337–344. 2017. View Article : Google Scholar : PubMed/NCBI
10	Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO and Green AR: Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 29:1949–1955. 2011. View Article : Google Scholar : PubMed/NCBI
11	Pagès F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, et al: In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 27:5944–5951. 2009. View Article : Google Scholar : PubMed/NCBI
12	Dunn GP, Bruce AT, Ikeda H, Old LJ and Schreiber RD: Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol. 3:991–998. 2002. View Article : Google Scholar : PubMed/NCBI
13	Tang J, Yang Z, Wang Z, Li Z, Li H, Yin J, Deng M, Zhu W and Zeng C: Foxp3 is correlated with VEGF-C expression and lymphangiogenesis in cervical cancer. World J Surg Oncol. 15:1732017. View Article : Google Scholar : PubMed/NCBI
14	Linehan DC and Goedegebuure PS: CD25+CD4+ regulatory T-cells in cancer. Immunol Res. 32:155–168. 2005. View Article : Google Scholar : PubMed/NCBI
15	Ménétrier-Caux C, Gobert M and Caux C: Differences in tumor regulatory T-cell localization and activation status impact patient outcome. Cancer Res. 69:7895–7898. 2009. View Article : Google Scholar : PubMed/NCBI
16	Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL and Banham AH: Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 24:5373–5380. 2006. View Article : Google Scholar : PubMed/NCBI
17	Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Lee AH, Ellis IO and Green AR: An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. Breast Cancer Res Treat. 127:99–108. 2011. View Article : Google Scholar : PubMed/NCBI
18	Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, Biota C, Doffin AC, Durand I, Olive D, et al: Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 69:2000–2009. 2009. View Article : Google Scholar : PubMed/NCBI
19	Liu F, Lang R, Zhao J, Zhang X, Pringle GA, Fan Y, Yin D, Gu F, Yao Z and Fu L: CD8⁺ cytotoxic T cell and FOXP3⁺ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat. 130:645–655. 2011. View Article : Google Scholar : PubMed/NCBI
20	Wang ZK, Yang B, Liu H, Hu Y, Yang JL, Wu LL, Zhou ZH and Jiao SC: Regulatory T cells increase in breast cancer and in stage IV breast cancer. Cancer Immunol Immunother. 61:911–916. 2012. View Article : Google Scholar : PubMed/NCBI
21	Andergassen U, Kölbl AC, Mahner S and Jeschke U: Real-time RT-PCR systems for CTC detection from blood samples of breast cancer and gynaecological tumour patients (Review). Oncol Rep. 35:1905–1915. 2016. View Article : Google Scholar : PubMed/NCBI
22	Chong MH, Zhao Y, Wang J, Zha XM, Liu XA, Ling LJ, Du Q and Wang S: The dynamic change of circulating tumour cells in patients with operable breast cancer before and after chemotherapy based on a multimarker QPCR platform. Br J Cancer. 106:1605–1610. 2012. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Mikhitarian K, Martin RH, Ruppel MB, Gillanders WE, Hoda R, del Schutte H, Callahan K, Mitas M and Cole DJ: Detection of mammaglobin mRNA in peripheral blood is associated with high grade breast cancer: Interim results of a prospective cohort study. BMC Cancer. 8:552008. View Article : Google Scholar : PubMed/NCBI
25	Mego M, Gao H, Cohen EN, Anfossi S, Giordano A, Tin S, Fouad TM, De Giorgi U, Giuliano M, Woodward WA, et al: Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. Oncotarget. 8:35656–35668. 2017. View Article : Google Scholar : PubMed/NCBI
26	Mego M, Gao H, Cohen EN, Anfossi S, Giordano A, Sanda T, Fouad TM, De Giorgi U, Giuliano M, Woodward WA, et al: Circulating tumor cells (CTC) are associated with defects in adaptive immunity in patients with inflammatory breast cancer. J Cancer. 7:1095–1104. 2016. View Article : Google Scholar : PubMed/NCBI
27	Benoy IH, Elst H, Philips M, Wuyts H, Van Dam P, Scharpé S, Van Marck E, Vermeulen PB and Dirix LY: Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Br J Cancer. 94:672–680. 2006. View Article : Google Scholar : PubMed/NCBI
28	Zamarron BF and Chen W: Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci. 7:651–658. 2011. View Article : Google Scholar : PubMed/NCBI
29	Kallergi G, Politaki E, Alkahtani S, Stournaras C and Georgoulias V: Evaluation of isolation methods for circulating tumor cells (CTCs). Cell Physiol Biochem. 40:411–419. 2016. View Article : Google Scholar : PubMed/NCBI
30	Curiel TJ: Tregs and rethinking cancer immunotherapy. J Clin Invest. 117:1167–1174. 2007. View Article : Google Scholar : PubMed/NCBI
31	Krishnamurthy S, Cristofanilli M, Singh B, Reuben J, Gao H, Cohen EN, Andreopoulou E, Hall CS, Lodhi A, Jackson S, et al: Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer. 116:3330–3337. 2010. View Article : Google Scholar : PubMed/NCBI
32	Chen Y, Zou TN, Wu ZP, Zhou YC, Gu YL, Liu X, Jin CG and Wang XC: Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigen-positive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer. Int J Biol Markers. 25:59–68. 2010. View Article : Google Scholar : PubMed/NCBI
33	Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 6:295–307. 2006. View Article : Google Scholar : PubMed/NCBI
34	Liu S, Foulkes WD, Leung S, Gao D, Lau S, Kos Z and Nielsen TO: Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Breast Cancer Res. 16:4322014. View Article : Google Scholar : PubMed/NCBI
35	West NR, Kost SE, Martin SD, Milne K, Deleeuw RJ, Nelson BH and Watson PH: Tumour-infiltrating FOXP3+ lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br J Cancer. 108:155–162. 2013. View Article : Google Scholar : PubMed/NCBI
36	Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, et al: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 169:2756–2761. 2002. View Article : Google Scholar : PubMed/NCBI
37	Li CH, Kuo WH, Chang WC, Huang SC, Chang KJ and Sheu BC: Activation of regulatory T cells instigates functional down-regulation of cytotoxic T lymphocytes in human breast cancer. Immunol Res. 51:71–79. 2011. View Article : Google Scholar : PubMed/NCBI
38	Chiba T, Ohtani H, Mizoi T, Naito Y, Sato E, Nagura H, Ohuchi A, Ohuchi K, Shiiba K, Kurokawa Y and Satomi S: Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: Possible association with suppression of micrometastasis. Br J Cancer. 91:1711–1717. 2004. View Article : Google Scholar : PubMed/NCBI
39	Campbell MJ, Scott J, Maecker HT, Park JW and Esserman LJ: Immune dysfunction and micrometastases in women with breast cancer. Breast Cancer Res Treat. 91:163–171. 2005. View Article : Google Scholar : PubMed/NCBI